Potential Resistance Mechanisms Exhibited by Cystic Fibrosis Patients Against SARS-CoV-2

Potential Resistance Mechanisms Exhibited by Cystic Fibrosis Patients Against SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the 2019 coronavirus disease pandemic. The virus primarily spreads through person-to-person contact via aerosols and droplets, contributing to high case numbers and related morbidities. SARS-CoV-2 targets the resp...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yasmin K. Elsharabassi, Nuha T. Swaidan, Mohamed M. Emara
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Viruses
Subjects:	SARS-CoV-2 COVID-19 cystic fibrosis ACE2 receptor TMPRSS2 CFTR gene
Online Access:	https://www.mdpi.com/1999-4915/17/7/919
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ACE2 and TMPRSS2 gene expression is reduced acutely in SARS-CoV-2 patients but returns to normal with recovery
by: Vanessa Hui En Chen, et al.
Published: (2025-04-01)

Host susceptibilities and entry processes of SARS-CoV-2 Omicron variants using pseudotyped viruses carrying spike protein
by: Alexandria Zabiegala, et al.
Published: (2025-05-01)

Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2
by: Shuhei Higuchi, et al.
Published: (2025-08-01)

Preventive effect of flavor/fragrance components on SARS-CoV-2 infections
by: Hidenobu Senpuku, et al.
Published: (2025-01-01)

Cystic Fibrosis and Reproductive Outcomes: The Latest Insights into Fertility and Pregnancy
by: Weronika Małagocka, et al.
Published: (2025-01-01)

A descriptive cohort study of pregnancy and parenthood in women with cystic fibrosis
by: Aleksandra Duffy, et al.
Published: (2025-07-01)

Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
by: Nemirajaiah, S.
Published: (2021-08-01)

Characterization of key spike RBD residues influencing SARS-CoV-2 variant adaptation to avian ACE2
by: Weitong Yao, et al.
Published: (2025-07-01)

Bat SARS-Like WIV1 coronavirus uses the ACE2 of multiple animal species as receptor and evades IFITM3 restriction via TMPRSS2 activation of membrane fusion
by: Mei Zheng, et al.
Published: (2020-01-01)

Epithelial response to IFN‐γ promotes SARS‐CoV‐2 infection
by: Julian Heuberger, et al.
Published: (2021-03-01)

Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1
by: Nianzhen Chen, et al.
Published: (2024-10-01)

Relationship of ACE1 and ACE2 genetic polymorphisms on SARS-CoV-2 infection and severity of symptoms in different regions of Iraq
by: Bilal Ali Khashan, et al.
Published: (2024-02-01)

Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation
by: Corrado Tagliati, et al.
Published: (2024-10-01)

Computational electrostatic engineering of nanobodies for enhanced SARS−CoV−2 receptor binding domain recognition
by: Zafar Iqbal, et al.
Published: (2025-03-01)

It Takes All of Us: How the Cystic Fibrosis Foundation Is Supporting States in Advancing Cystic Fibrosis Newborn Screening
by: Mary Dwight, et al.
Published: (2025-05-01)

Genetic variants in TMPRSS2 influence SARS-CoV-2 infection susceptibility within Mexican Mestizos
by: Rebeca I. Montero, et al.
Published: (2025-04-01)

Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
by: Burkhard Tümmler, et al.
Published: (2025-05-01)

Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells
by: Sunhee Lee, et al.
Published: (2020-01-01)

Basic implications on three pathways associated with SARS-CoV-2
by: Jong hoon Lee, et al.
Published: (2025-04-01)

Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review
by: Ammar Ahmed, et al.
Published: (2024-12-01)

Mild and moderate manifestations of SARS-CoV-2 infection, including hospitalization, in children and adolescents with cystic fibrosis
by: Fábia Regina dos Santos, et al.
Published: (2025-05-01)

Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
by: Nataliya Yu. Kashirskaya, et al.
Published: (2021-12-01)

Cystic Fibrosis assessment in infertile couples: genetic analysis trough the Next Generation Sequencing technique
by: Elena D’Alcamo, et al.
Published: (2022-05-01)

A severe early presentation of cystic fibrosis in an infant with a homozygous c.1375_1383del CFTR variant- a case report
by: Abdullah Yousef, et al.
Published: (2025-08-01)

Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers
by: Karthikeyan Subbarayan, et al.
Published: (2025-03-01)

The ACE2 Receptor from Common Vampire Bat (<i>Desmodus rotundus</i>) and Pallid Bat (<i>Antrozous pallidus</i>) Support Attachment and Limited Infection of SARS-CoV-2 Viruses in Cell Culture
by: Abhijeet Bakre, et al.
Published: (2025-03-01)

Allergic bronchopulmonary aspergillosis as an initial manifestation of cystic fibrosis: Diagnostic and therapeutic implications in the era of CFTR modulators
by: Georgia Mitropoulou, MD, et al.
Published: (2024-11-01)

The Functional Impact of VX-770 on the Cystic Fibrosis Transmembrane Conductance Regulator Is Enduring and Increases the Constitutive Activity of This Channel in Primary Airway Epithelia Generated from Healthy Donors
by: Heidi J. Nick, et al.
Published: (2024-10-01)

Altered plasma levels of the SARS-CoV-2-related proteins ACE2 and TMPRSS2 in patients with Crohn’s disease
by: Jorge Sáez-Leyva, et al.
Published: (2024-12-01)

The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation
by: Ming-Shiu Lin, et al.
Published: (2025-06-01)

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
by: Raveen Rathnasinghe, et al.
Published: (2020-01-01)

ACE2 and TMPRSS2 genetic polymorphisms as potential predictors of COVID−19 severity and outcome in females
by: Sanja Matic, et al.
Published: (2024-12-01)

Disrupting SARS-CoV-2 Spike–ACE2 Interactions via Glycosaminoglycans in a Pseudoviral Study of Heparan Sulfate and Enoxaparin
by: Virginia Fuochi, et al.
Published: (2025-06-01)

Perspectives in MicroRNA Therapeutics for Cystic Fibrosis
by: Alessia Finotti, et al.
Published: (2025-01-01)

State of Knowledge About Thyroid Cancers in the Era of COVID-19—A Narrative Review
by: Agnieszka Bronowicka-Szydełko, et al.
Published: (2024-12-01)

Heterogeneity of phenotypic manifestations of cystic fibrosis in children and predictors of the disease severity
by: K. V. Skriabina, et al.
Published: (2022-12-01)

Phenotype and Genotype of Two Taiwanese Cystic Fibrosis Siblings and a Survey of Delta F508 in East Asians
by: Chao-Jen Lin, et al.
Published: (2008-12-01)

An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters
by: Esther Föderl-Höbenreich, et al.
Published: (2025-04-01)

Critical amino acid residues in human ACE2 for SARS-CoV-2 spike protein binding and virus entry
by: Weiyi Chen, et al.
Published: (2025-08-01)

Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate
by: Endika Prieto-Fernández, et al.
Published: (2021-01-01)